Gómez-García Francisco, Ruano Juan, Gay-Mimbrera Jesús, Aguilar-Luque Macarena, Sanz-Cabanillas Juan L, Hernández Romero José L, Garcia-Nieto Antonio Velez
Department of Dermatology, Hospital Universitario Reina Sofía, Córdoba, Spain.
Immuno-mediated Inflammatory Skin Diseases Lab, Instituto Maimónides de Investigación Biomédica de Córdoba (IMIBIC)/Hospital Universitario Reina Sofía/Universidad de Córdoba, Córdoba, Spain.
Dermatol Ther (Heidelb). 2018 Jun;8(2):195-202. doi: 10.1007/s13555-018-0235-4. Epub 2018 Apr 6.
The interleukin (IL)-1 pathway has been identified as being involved in inflammatory and neoplastic skin diseases such as psoriasis, atopic dermatitis, neutrophilic dermatosis, melanoma, and squamous cell carcinoma. Drugs developed to target the IL-1 pathway are currently used to treat these pathologies, and although they are becoming more selective, they are not exempt from adverse events and high costs. Integrating the best research evidence with clinical experience and patient needs has been shown to improve care, health, and cost outcomes. This is because evidence-based guidelines rank interventions according to cost-effectiveness. However, evidence on this topic is scarce for several reasons. First, although randomized clinical trials currently provide the best evidence, they are not always available. Second, there are no secondary scientific studies that summarize the use of IL-1-targeting agents in dermatology. We therefore sought to develop an a priori protocol for broadly reviewing the available evidence on the use of IL-1-targeting drugs in the treatment of dermatological diseases.
We used the latest methodology to perform a scoping review as described in the Joanna Briggs Institute manual.
RESULTS/DISCUSSION: Developing and applying a methodology for evidence synthesis promotes reproducibility and increases the validity of secondary scientific investigations, making it the optimal strategy for scientifically synthesizing a broad field such as the indications for and the mechanisms of action, efficacies, safety, and costs of IL-1-targeting drugs in the treatment of dermatological diseases. Quantitative synthesis facilitates the detection of knowledge gaps and the identification of new questions that can be addressed through systematic reviews. We present an a priori protocol for exploring the available evidence on this topic.
白细胞介素（IL）-1信号通路已被证实参与了多种炎症性和肿瘤性皮肤病，如银屑病、特应性皮炎、嗜中性皮病、黑色素瘤和鳞状细胞癌。目前，针对IL-1信号通路开发的药物被用于治疗这些疾病，尽管这些药物的选择性越来越高，但仍存在不良事件和高成本问题。将最佳研究证据与临床经验和患者需求相结合已被证明可以改善医疗、健康和成本效益。这是因为循证指南根据成本效益对干预措施进行排序。然而，由于多种原因，关于这一主题的证据很少。首先，尽管随机临床试验目前提供了最佳证据，但并非总能获得。其次，目前尚无二次科学研究总结IL-1靶向药物在皮肤科的应用情况。因此，我们试图制定一个先验方案，以广泛回顾关于使用IL-1靶向药物治疗皮肤病的现有证据。
我们采用了最新的方法，按照乔安娜·布里格斯研究所手册中所述进行了范围综述。
结果/讨论：开发和应用证据综合方法可提高可重复性，并增加二次科学研究的有效性，使其成为科学综合广泛领域（如IL-1靶向药物治疗皮肤病的适应症、作用机制、疗效、安全性和成本）的最佳策略。定量综合有助于发现知识空白，并识别可通过系统综述解决的新问题。我们提出了一个先验方案，以探索关于这一主题的现有证据。
